These findings support the concept that targeting YAP1 or supplementing A. muciniphila may boost anti-PD-1 immunotherapy efficacy in HCC by modifying the gut–liver axis and immune landscape. This evidence concerns the gene YAP1 and hepatocellular carcinoma.